INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive hematological disorder in which the hematopoietic progenitor cells lose their ability to differentiate normally and continue to proliferate. Fms-like tyrosine receptor kinase-3 (FLT3) plays an important role in normal hematopoiesis and leukemogenesis and is expressed in most of AML blasts 1 . In 20-25% of AML patients, the FLT3 gene acquires an internal tandem duplication in the juxtamembrane domain of FLT3 (FLT3-ITD) and this is associated with poor prognosis 2, 3 . FLT3 point mutations within the activation loop of the tyrosine kinase domain (FLT3-TKD) have also been detected in approximately 7% of AML patients 4 . FLT3-ITD or -TKD mutants undergo constitutive autophosphorylation of FLT3, causing aberrant signaling activation of several pathways such as Ras/MAP, JAK/STAT5, and AKT [5] [6] [7] . Activated FLT3-kinase mutations eventually induces transformation and tumorigenesis in hematopoietic cells and suppresses normal myeloid differentiation and therefore are attractive therapeutic targets to treat AML.
A number of receptor tyrosine kinase inhibitors (TKIs) targeting FLT3 have been developed and clinically examined in AML patients 8, 9 ; Midostaurin (PKC412), the multiple kinase inhibitor in Phase III trials in combinational chemotherapy 10 , Sorafenib in Phase I trials in relapsed/refractory AML patients 11 , and Quizartinib (AC220), a selective FLT3 inhibitor in Phase II trials 12 . PKC412 induced a 92% complete remission (CR) rates in FLT3-mutated AML in combinational chemotherapy 13 ,
Sorafenib achieved a 23% CR in 65 FLT3-ITD AML patients after chemotherapy or allogeneic hematopoietic stem cell transplantation 11 and AC220 led to a 3-6% CR and 46-54% composite CR rate in relapsed/ refractory 190 FLT3-ITD positive AML patients 14, 15 .
The development of drug-resistance during the treatment of hematological malignance has been a challenging issue for TKIs. Recent evidences suggest that the majority of patients treated with single FLT3 inhibitor experienced only transient and partial response due to the development of drug resistance, which hinders treatment with FLT3-TKIs [16] [17] [18] . Various factors including point mutations, plasma inhibitory activity (PIA), protective effect by bone marrow stromal cells, and high levels of
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From FLT3 ligand (FL) have been identified to confer FLT3 inhibitors drug resistance. Point mutations within the kinase domain of FLT3-ITD especially at the position of N676, F691, and D835 lead to substantial resistance to AC220 and PKC412 16, 19 . Additional resistance mutations to AC220 have also been described using in vitro models 20 . Drug resistance comes from PIA where the inhibition of PKC412 and CEP701 against FLT3 autophosphorylation was dramatically decreased in human plasma milieu 21 . The bone marrow microenvironment also contributes to the reduction of drug sensitivity in vivo. It was shown that bone marrow stromal cells support the survival of neighboring blast cells, resulting in the long-term survival and growth of leukemia cells [22] [23] [24] [25] [26] . The increased secretion of FLT3 ligand after induction therapy of Cytarabine was also known to attenuate efficacy of FLT3 inhibitors 27 . Therefore, there is an unmet need for the next generation FLT3 inhibitor to overcome drug resistance.
Here, we report that a novel inhibitor G-749 with a unique kinase inhibition profile is very potent medium supplemented with 10% fetal bovine serum (FBS) or calf bovine serum, 2 mM of Lglutamine and 1% of the antibiotics penicillin/streptomycin and cultured in a humidified atmosphere at 37℃ with 5% CO 2 . G-749 was synthesized at Genosco (Cambridge, MA). Its synthetic process is described in Supplementary Figure 1 and Method. The FLT3 inhibitors AC220 and PKC412 were purchased from LC Laboratories.
Cell proliferation, Apoptosis, and FACS analysis
Cells were seeded at a density of 2 ATPLite assay (Perkin-Elmer). Caspase-3/7 activity was measured by using the Caspase-Glo 3/7 assay (Promega).
For flow cytometry analysis experiments, MV4-11 cells were washed and resuspended in binding 
Western Blot analysis and ELISA
The phospho-FLT3 ELISA kit was purchased from Cell Signaling Technology and performed according to manufacturer's protocol. The detail protocol of Western analysis is described in Supplementary Method.
Patient Samples
In accordance with the Declaration of Helsinki, bone marrow mononuclear cells from AML patients were collected with informed consent. Institutional Review Board (IRB) approval was obtained from Cryopreserved samples were thawed and incubated with culture medium enriched to 20% FBS for 90 minutes before experimental procedures. Only samples with >70% viability were used for proceeding test. For blast viability, the blasts were treated with FLT3 inhibitors for 72 hours, supplemented with 50 ng/mL IL-3 and 50 ng/mL SCF. Their viability was determined by an ATPLite assay.
In vivo mouse models
The subcutaneous MV4-11 tumor model and the bone marrow engrafted model are described in Supplementary Method. For statistical analysis, Analysis of variance (ANOVA) was performed by Prism 5.0 to examine statistical difference (detail in Supplementary Method).
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RESULTS
Biochemical properties and selectivity of G-749
A novel small molecule FLT3 kinase inhibitor, G-749 was designed and synthesized using structure- To evaluate its kinase selectivity, 100 nM G-749 was initially challenged against 282 kinases using the Millipore Kinase Profiler (Supplemental Table 2 ). Major kinases inhibited by G-749 were further selected to determine their IC 50 potency (Supplemental Table 1 ). This assay revealed that G-749 displayed a unique inhibition pattern. It was highly potent against FLT3, FLT3-D835Y, and Mer (1 nM of each kinase IC 50 ). The receptor tyrosine kinases (Ret, FLT1, Axl, Fms, FGFR1, and FGFR3) and serine/threonine kinases (Aurora B and C) were also inhibited with an IC 50 value of 9-30 and 6-24 nM, respectively. Other kinases including c-KIT, PDGFRs, and EGFR were not potently inhibited (IC 50 value of > 300 nM); however, their mutants were significantly inhibited. Collectively, G-749 was identified as a novel and potent FLT3 inhibitor with a unique kinase inhibitory profile.
Antiproliferative activity on leukemia cells
The antiproliferative activity of G-749 was assessed in several leukemia cell lines. G-749 showed strong antiproliferation of leukemia cells addicted to FLT3-ITD (MV4-11 and Molm-14) in a dose dependent manner, whereas it did not potently inhibit proliferation of leukemia cells without FLT3 
Potent inhibition of G-749 against FLT3 mutants
To evaluate whether G-749 could inhibit several FLT3 mutants causing drug resistance, we examined 
Effective inhibition of FLT3 pathways in high FLT3 ligand milieu
We examined the potency of G-749 in high concentration of FL milieu. Exogenous FL addition led to 
1
Potent inhibitory activity in normal and patient human plasma milieu
We examined the potency of G-749 in normal and patient plasma milieu to assess plasma inhibitory activity (PIA). G-749 and AC220 equally inhibited p-FLT3 in culture medium and normal human plasma milieu in a dose dependent manner but PKC412 did not inhibit p-FLT3 in plasma milieu even at the high concentration of 1 μ M ( Figure 3A top & middle), which was further confirmed by ELISA analysis (Supplemental Figure 9 ).
We further examined the potency of G-749 and AC220 by using the bone marrow plasma from 10 AML patients who achieved complete remission (CR, n=7) or relapsed (n=3) after induction therapy with Cytarabine (Supplemental Table 3 ). Western blot analysis revealed that G-749 consistently To address the lost potency of AC220 in relapsed patient millieu, we examined changes in p-FLT3 in normal plasma supplemented with FL and found that AC220 showed potent inhibition of p-FLT3
( Figure 3A , bottom), thus FL in plasma does not contribute to the lost potency. In addition, the plasma protein binding of AC220 and G-749 is about 98% and 99%, respectively so that the free form of the compound is not responsible for the reduction in potency. Therefore, it is reasonable that other unknown factors in patient plasma may be involved in impeding the efficacy of FLT3 inhibitor including AC220 but excluding G-749 and remain to be addressed. Collectively, these PIA studies clearly suggest that G-749 effectively and potently inhibits FLT3 and downstream effectors in relapsed patient plasma.
2
Effective inhibition in stroma protecting milieu
We investigated the antileukemic activity of FLT3 inhibitors in drug-resistant milieu provided by bone marrow stromal cells known to promote leukemia cell survival [22] [23] [24] [25] 
3
Effective anti-tumor activity in mouse models
To assess in vivo pharmacodynamic effect of G-749, a single dose of G-749 HCl salt (10 mg/kg) was orally administrated to subcutaneous MV4-11 xenograft mice and showed sustained inhibition of p-FLT3, p-STAT5, and p-ERK1/2 ( Figure 5A-B) . These data indicate that G-749 effectively inhibits FLT3 pathway and its inhibiton lasts for 24 hours. Therefore, once a day oral dosing was expected to be sufficient for in vivo efficacy in the mouse model.
To examine its anti-tumor efficacy, G-749 HCl salt was orally and quague die administrated for 28 days to the MV4-11 xenograft mice. Significant inhibition of tumor growth was observed in the 3 mg/kg/day dosing group from 4 days onward and apparent tumor regression was seen in the 10 and 30 mg/kg/day dosing group ( Figure 5C ). The mice dosed with 30 mg/kg/day were subsequently monitored for additional 28 days after dosing stopped to examine if the tumor grows back. There was no tumor regrowth up to 28 days suggesting complete tumor regression. Additionally, in this study, weight loss and signs of gross toxicity were not observed in any dose group (Supplemental Figure 12) .
We confirmed anti-tumor efficacy in an orthogonal model of bone marrow engraftment 47 using Molm-14 cells, which physiologically differs from the subcutaneous MV4-11 xenograft model. In engrafted NOD/SCID mice, vehicle-treated mice showed expected clinical symptoms such as hind-limb paralysis, rough coat and decreased activity and died within 9 days. But both 10 and 20 mg/kg/day dosing groups showed increased survival in dose-dependent manner ( Figure 5D ). Collectively, G-749 yields effective in vivo anti-tumor activity in two different leukemia animal models and is expected to yield great efficacy in clinical trials.
Potent anti-leukemia activity in blasts of AML patients
To evaluate the antileukemia activity in primary cells, bone marrow blasts were obtained from 16
AML patients diagnosed as FLT3-WT, -ITD, -D835Y, and -ITD/D835Y (Supplemental Table 4 ). The overall magnitude of antileukemic activity of G-749 was more effective than that of AC220 and Figure 6A, Supplemental Figure 13) . Remarkably, the antileukemic response of G-749 was about 75% to the blasts with FLT3-D835Y and about 50% to those with FLT3-ITD/D835Y that showed no or little response to AC220. These data are consistent with the findings from the BaF3 model cells.
PKC412 (
We further determined whether the antileukemic activity of G-749 couples with the inhibition of FLT3 pathways in patient blasts. In the patients 11 and 12 blasts with FLT3-ITD, G-749 showed more potent inhibition of p-FLT3 and p-ERK1/2 than AC220 and PKC412. In the patients 13 and 14 blasts with FLT3-D835Y, G-749 also showed more potent inhibition against p-FLT3 than AC220. Both G-749 and PKC412 effectively inhibited p-ERK1/2 in patients 13 and 14 blasts. Remarkably, in cases where they did not inhibit the p-FLT3 (patient 12), AC220 and PKC412 potently inhibited p-STAT5 ( Figure 6D ). These data suggest that G-749 shows inhibition of p-FLT3 and downstream effectors in patient blasts, regardless of FLT3 mutation status, eventually resulting in efficient antileukemic activity against blasts of AML patients. FLT3 TKD mutants especially at N676, F691, and D835 were identified to confer resistance to PKC412 and AC220 16, 19 . In this study, we demonstrated potent inhibitory activity of G-749 against 
